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Abstract
Background: Microarrays permit biologists to simultaneously measure the mRNA abundance of
thousands of genes. An important issue facing investigators planning microarray experiments is how
to estimate the sample size required for good statistical power. What is the projected sample size
or number of replicate chips needed to address the multiple hypotheses with acceptable accuracy?
Statistical methods exist for calculating power based upon a single hypothesis, using estimates of
the variability in data from pilot studies. There is, however, a need for methods to estimate power
and/or required sample sizes in situations where multiple hypotheses are being tested, such as in
microarray experiments. In addition, investigators frequently do not have pilot data to estimate the
sample sizes required for microarray studies.
Results: To address this challenge, we have developed a Microrarray PowerAtlas [1]. The atlas
enables estimation of statistical power by allowing investigators to appropriately plan studies by
building upon previous studies that have similar experimental characteristics. Currently, there are
sample sizes and power estimates based on 632 experiments from Gene Expression Omnibus
(GEO). The PowerAtlas also permits investigators to upload their own pilot data and derive power
and sample size estimates from these data. This resource will be updated regularly with new
datasets from GEO and other databases such as The Nottingham Arabidopsis Stock Center
(NASC).
Conclusion: This resource provides a valuable tool for investigators who are planning efficient
microarray studies and estimating required sample sizes.

Background
Planning microarray studies provides unique challenges
to investigators with respect to estimating power and the
sample size required for a study. The questions proposed
may be quite general and exploratory, such as "which

genes are differentially expressed in response to a given
treatment?" A microarray study should have a high probability to answer, at least in part, the questions and
hypotheses being proposed [loosely speaking, power or in
our case Expected Discovery Rate (EDR)]. It should also
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Table 1: Quantities of interest in microarray experiments

Genes not declared significant at designated thereshold
Genes declared significant at designated thereshold

have a high probability that those genes declared significant are truly differentially expressed (i.e. the 'True Positive' probability should be high). Sample size is a critical
determinant of statistical power and expected error rates.
In traditional biomedical studies, investigators test one or
at most a few hypotheses. This is not the case in microarray studies. Each treatment or group comparison involves
the testing of every gene on the chip, which may number
in the 10,000's. Some microarray experiments may
involve multiple groups; thus the total number of hypotheses tested in a microarray experiment can run in the
100,000 s or more. In addition, the effects size and variance for each hypothesis may be different; resulting in different power estimates for each and every gene by
treatment comparison.
Some investigators have proposed approaches to estimating required sample size for microarray research [2-4], but
most of these methods calculate power based upon an
arbitrary level of change being biologically relevant and
constant across all genes. These methods do not take into
account the amount of variability in each gene nor specify
a hypothesized distribution of effect sizes, and do not
incorporate some of the recently developed approaches to
account for multiple testing in high-dimensional biology(HDB) [5].
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Estimated PTP, PTN, and EDR for the GDS486 [17] dataset
for a variety of samples sizes at an alpha level of 0.05.
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Calculating required sample sizes for a study requires an
estimate of the variability in the dependent variable, in
the case of microarray studies the genes' expression levels.
This information is frequently derived from previous pilot
studies performed by the research team or from similar
data in the literature. Integrating information from pilot
studies that illustrate the variability of all the genes in a
study provides empirically driven and theoretically defensible sample size estimates. We have formalized such an
approach [5]. Rather than using traditional power (1-β)
we introduced the concept of Expected Discovery Rate
(EDR). EDR is the average power (see table 1 for a definition of A, B, C, and D) for all genes for which the null
hypothesis is false in an experiment. EDR is the E [Q]
where Q = D/(D+B) if D+B>0 and Q = 0 otherwise and
can be interpreted as the expected proportion of genes
that are truly differentially expressed that will be declared
to be differentially expressed. Microarray studies are
affected by multiple testing issues; thus, when considering
power studies one must not only consider the alpha (significance) level cut-off used, but also the expected proportion of genes that are True Positives (PTP), which is
similar in concept to the False Discovery Rate. The PTP
may be defined as (again A, B, C and D are defined in table
1) the E [R] where R = D/(C+D) if C+D>0 and R = 0 otherwise. The PTP is the expected proportion of genes that
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For the GDS486 dataset [18] the EDR is presented across a
variety of sample sizes and alpha levels.
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For the GDS486 dataset [19] the PTP is presented across a
variety of sample sizes and alpha levels.
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For the GDS75 dataset [21] the EDR is presented across a
variety of sample sizes and alpha levels.

are declared significantly differentially expressed between
the two samples that are actually differentially expressed
between the two populations. A higher value for PTP is
considered more desirable. The software also provides the
Probability of a True Negative (PTN), which is the expected
proportion of genes that are not declared significantly differentially expressed between the two samples that are
actually not differentially expressed between the two populations. The use of EDR, PTP, and α provides a coherent
way to estimate the sample size required for microarray
research that is consistent with current approaches to analyzing microarray data and conceptualizing the process of
massive multiple hypothesis testing in HDB research
[6,7]. The PowerAtlas implements the methods developed
by Gadbury et al [5] and adds further functionality.

The PowerAtlas works in two ways. Firstly, investigators
may upload their own pilot data and extrapolate out the
EDR, PTN, and PTP for a variety of sample sizes and α
(type 1 error rate) level combinations. Secondly, many
investigators do not have the opportunity to conduct their
own pilot microarray study, but this need not stop an
investigator. Given that many journals now require
authors to place microarray data in public databases [8]
before publication, investigators may draw upon these
public data as pilot information. We have developed the
PowerAtlas to assist investigators in the use of these public
data to estimate the sample sizes required for well-powered studies. We have downloaded all data from Gene
Expression Omnibus [9], reanalyzed it, and processed it
with the methods developed in Gadbury et al [5]. There-
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Estimated PTP, PTN, and EDR for the GDS75 [20] dataset
for a variety of samples sizes at an alpha level of 0.05.
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Table 3: Estimated EDR and PTP for sample size of 7 per group at alpha levels of 0.05 and 0.001 extrapolated from a sample size of 3
(row 2) from the PKD data and the estimated EDR and PTP group at alpha levels of 0.05 and 0.001 calculated in the follow up study of
7 mice per group.

Pilot of 3 per group
Experiment of 7 per group

Estimated EDR for SS 7
at α = 0.05

Estimated PTP for SS 7
at α = 0.05

Estimated EDR for SS 7
at α = 0.001

Estimated PTP for SS 7
at α = 0.001

0.415009
0.538771

0.809616
0.772419

0.119791
0.133711

0.985287
0.976347

after, we have put the power and sample size calculations
for many of the datasets into a readily accessible and
searchable database [1]. It should be stressed that no one
study is a perfect replicate of the study an investigator
wishes to conduct, but similar studies can give a sense of
the plausible ranges of sample sizes. We recommend that
investigators examine several related experiments to get a
sense of the sample size required for robust EDR and high
PTP.

puter. An investigator simply accesses the PowerAtlas [1]
and selects the appropriate link to use public data or the
investigator's study-specific data.

Usage of the PowerAtlas
No registration is required to use the PowerAtlas, nor are
any programs or applets pushed to an investigator's com-

The data in the PowerAtlas are taken directly from GEO. As
long as it meets the requirements outlined in 'Using Existing Public Data' the data is included in the PowerAtlas.
However, the data in GEO can be quite variable, due to
any number of reasons, including, but not limited to, the
image processing algorithm, normalization, and inferential statistical procedure used in the analysis. Thus when
using public data as a basis for planning future studies, an
investigator should consider the results from several datasets, consult the primary sources (GEO GDS files and journal publications of the data), and have a reasonable
understanding of the idiosyncrasies and applicability of
each dataset to the proposed experiment before using the
data. In addition, since each lab processes and handles
samples and runs microarrays slightly differently, when
possible, estimates of power should be based upon an
investigator's own pilot data, which will be more accurate

Figure
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Idealized representation of the distribution of p-values under
the null hypothesis (no difference in gene expression
between the two groups) for a valid test. The dotted Blue
line is the expected distribution of p-values if the treatment
has no effect and the solid Green line is the mixed-model
[23] fit of the p-value constrained to be monotonically nondecreasing.
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More realistic representation of the distribution of p-values
under the null hypothesis (no difference in gene expression
between the two groups) for a valid test. The dotted Blue
line is the expected distribution of p-values if the treatment
has no effect and the solid Green line is the mixed-model
[23] fit of the p-value constrained to be monotonically nondecreasing.

Designing a microarray study with the appropriate
number of replicates is cost efficient. The use of the PowerAtlas will not only prevent investigators from using too
many samples in a group, resulting in wasted money; but
will also limit wasting money on experiments that have
too few replicates to have sufficient power to yield good
results.
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Distribution of p-values when there is a difference in the
gene expression between the two groups for some of the
genes, but not all of the genes. This distribution is monotonically non-increasing from 0 to 1. The dotted Blue line is the
expected distribution of p-values if the treatment has no
effect and the solid Green line is the mixed-model [23] fit of
the p-value constrained to be monotonically non-decreasing.

for an investigator's future experimental power than will
extrapolations from other investigators' data.
Using the investigators' own data
To use the PowerAtlas with an investigator's own data a list
of p-values generated using a valid statistical method must
be available. Currently the PowerAtlas generates sample
sizes for two group comparisons only for any valid statistical test [10]. Then use the following instructions:

• The investigator must possess/generate a tab delimited
file with one p-value per gene/feature for the main
hypothesis of interest with each p-value located on its
own line. There should be no identifiers for genes. All pvalues from all genes on a chip/array should be included.
• The file with p-values is uploaded to the web site.
• The investigator then enters the sample sizes (N1 and
N2) for each of the groups used to calculate the p-values.
• The investigator then may either use default or custom
settings for the sample sizes, significance (α) thresholds,
and number of iterations for the bootstrap to be used for
estimating power.
• The investigator selects submit. For a sense of runtime,
from an initial set of 12,500 p-values with EDR, PTP, and
PTN being calculated for 14 sample sizes and six thresholds, the analysis takes 3–10 minutes.

http://www.biomedcentral.com/1471-2105/7/84
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Distribution of p-values for a dataset in GEO that does not
follow one of the possible distributions for p-values The dotted Blue line is the expected distribution of p-values if the
treatment has no effect and the solid Green line is the
mixed-model [23] fit of the p-value constrained to be monotonically non-decreasing.

• The investigator then will obtain a series of figures that
illustrate the EDR, PTP, and PTN for a variety of sample
sizes and significance (α) thresholds(examples are shown
in figures 1, 2, 3 for an Affymetrix dataset [11] and figures
4, 5, 6 for a cDNA experiment [12]). The investigator may
then choose the sample size and α level combination that
achieves the desired levels for EDR, PTP, and PTN.
Using existing public data
We have downloaded and processed all data that was in
GEO's ftp site as of Oct 1, 2004 into the PowerAtlas. One
type of information GEO allows to be entered is the group
to which a chip belongs. We conducted a pooled variance
t-test on all possible two-group intraGDS (GDS is the
GEO definition of an experiment) comparisons from all
datasets within GEO. During analysis some datasets were
removed. Reasons for removal include: A) The data per
chip was incomplete, for example, due to masking or
selecting genes based on present or absent calls. B) The pvalues did not follow the expected possible distributions
(monotonically non-decreasing from 0 to 1). Figure 7 and
8 illustrate a null data set (no more genes are significant
than are expected at random). Figure 9 illustrates a typical
p-value distribution for a good dataset for which the null
is false for some, but not all genes. Figures 10, 11, 12 represent distributions of p-values seen while processing
GEO that do not fit the expected distributions and thus
would be listed as NA. C) Only two group fully randomized cDNA experiments can be analyzed, which prevents some cDNA experiments, including all loop designs
and those that involve dye swaps unless in a balanced

Page 5 of 9
(page number not for citation purposes)

BMC Bioinformatics 2006, 7:84

Figureone
Distribution
follow
11 ofofthe
p-values
possible
fordistributions
a dataset in for
GEO
p-values
that does not
Distribution of p-values for a dataset in GEO that does not
follow one of the possible distributions for p-values. The dotted Blue line is the expected distribution of p-values if the
treatment has no effect and the solid Green line is the
mixed-model [23] fit of the p-value constrained to be monotonically non-decreasing. The dotted Blue line is the expected
distribution of p-values if the treatment has no effect and the
solid Green line is the mixed-model [23] fit of the p-value
constrained to be monotonically non-decreasing.

block design from being analyzed. [13-15]. D) Datasets
having fewer than two experimental groups and three
chips per group are also excluded.
To use the public data for estimating sample size:
• From the PowerAtlas web page an investigator selects the
option of using existing public data.
• The investigator makes a selection of desired chip type
(one or two channel) and the species of interest. At most,
one of each chip type or species of interest may be
selected. Alternatively, the investigator may also select
only a chip type or a species.
• A list of all experiments will appear that meet the selection criteria. The number of datasets can range from 0
(most bacteria on single channel chips) to more 200 for
Human and Mouse on single channel chips (see table 2).
• The investigator can read a brief description, taken
directly from GEO, of all the experiments and find those
that are most similar to their proposed experiment(s).
• The investigator then selects the checkbox to the left of
the desired datasets and press Submit to get additional
information.

http://www.biomedcentral.com/1471-2105/7/84
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Distribution of p-values for a dataset in GEO that does not
follow one of the possible distributions for p-values. The dotted Blue line is the expected distribution of p-values if the
treatment has no effect and the solid Green line is the
mixed-model [23] fit of the p-value constrained to be monotonically non-decreasing.

• The investigator receives a report with a link to the GEO
description should additional information be needed.
• There are also links to a printable HTML report that
includes a description of the dataset, the EDR, PTP, and
PTN (figures 1 and 4) at an α level of 0.05 as well as a
description of how to interpret the results.
• In datasets with more than 2 groups the two groups with
the largest sample sizes are given in the HTML report.
There is a link to jpeg images for the other IntraGDS comparisons in the data set. In addition there is a link to a
downloadable zip file that contains graphs illustrating the
EDR (figures 2 and 5), PTP (figures 3 and 6), and PTN for
a variety of α and sample sizes in a directory structure for
each two group comparison. There is also an Excel file
provided that contains the numbers underlying the figures.
Illustrative example of the accuracy and utility of the
PowerAtlas
We provide a concrete example for illustrative purposes.
In one study (unpublished) the RNA kidneys from individual mice that were homozygous for a PKDPH mutation were collected. Mice were selected from a F2 cross
that had a very high kidney length to width ratio (three
mice) or a very low length to width ratio (three mice). This
measure is one determinant of polycystic kidney disease
severity. The RNA was run on the Affymetrix Mu74Av2
array and processed with MAS 5.0 (Affymetrix, Inc, Emoryville, CA). Figure 13 illustrates the distribution of p-val-
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Table 2: Itemization of the number type and species of chips available. NA means power estimation is not available. See section "Using
existing public data" for possible explanations why the datasets may have be listed as NA.

Dual Channel

Dual Channel

Single Channel

Single Channel

Arabidopsis thaliana
Aspergillus parasiticus
Bacillus anthracis
Bos taurus
Caenorhabditis elegans
Campylobacter jejuni
Canis familiaris
Capra hircus
Chlamydomonas reinhardtii
Cricetulus griseus
Drosophila melanogaster
Drosophila simulans
Drosophila yakuba
Escherichia coli
Escherichia coli K12
Fundulus heteroclitus
Homo sapiens
Marmota monax
Mastomys natalensis
Mus musculus
Mycobacterium tuberculosis
Oncorhynchus mykiss
Oryza sativa
Pinus contorta
Rattus norvegicus
Rhodobacter sphaeroides
Saccharomyces cerevisiae
Saccharomyces pastorianus
Saccharum sp.
Salmo salar
Salmonella enterica
Sus scrofa
Viruses
Zea mays

Available
1
0
0
0
1
1
0
0
1
0
3
2
0
5
0
0
44
0
0
63
1
0
0
0
6
0
12
0
0
0
1
0
0
1

NA
10
1
2
3
2
1
0
0
0
1
9
0
2
1
0
0
34
0
0
14
0
4
2
0
8
0
41
0
0
2
0
1
0
0

Available
22
0
0
2
1
0
1
1
0
0
15
0
0
2
1
1
178
1
0
175
0
0
0
1
68
2
18
0
0
0
0
1
0
0

NA
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
35
1
1
58
0
0
0
0
13
2
1
1
1
0
0
0
1
0

TOTAL

142

138

490

115

ues for the 2-group comparison of the gene expression
levels between the high and low kidney length-to-width
ratio mice. These p-values were run through the PowerAtlas. We selected a target sample size of seven per group to
have an EDR of > 40% and PTP > 80% at α<0.05. An additional seven mice were run from each extreme of the kidney length-to-width ratio distribution. The distribution of
the p-values for the seven mice per group comparison is
given in figure 14. Table 3 illustrates the EDR and PTP at
α = 0.05 and 0.0001 for a sample size of seven per group
that were estimated from the initial sample of three per
group (row 2). These numbers are compared to the actual
EDR and PTP that were calculated at α = 0.05 and 0.0001
for the follow on study at a sample size of seven per group
(row 3). The numbers are remarkably similar.

Conclusion
The PowerAtlas provides investigators the option of using
their own pilot data or drawing from a public domain
microarray data sets to calculate sample sizes and statistical power for a proposed study. The overall goal is to estimate the sample size required to be able to answer the
hypothesis of interest with a high EDR and a high PTP
without using too many chips. Once the graphs and tables
most appropriate are identified (which may involve examining several datasets), the investigator must decide upon
the sample size to pursue. Unlike single hypothesis-driven
research, a huge number of genes often are typically differentially expressed in a single microarray experiment and a
study may yield many (often thousands) of significant
genes. It is generally difficult for a single laboratory to fol-
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Distribution of p-values for the comparison of RNA from 7
mice with PKDH mutations and a high kidney length to width
ratio and RNA from 7 mice with PKDH mutations and a low
kidney length to width ratio. The dotted blue line is the
expected distribution of p-values if the treatment has no
effect and the solid green line is the mixed-model [23] fit of
the p-value constrained to be monotonically non-decreasing.
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Distribution of p-values for the comparison of RNA from 3
murine with homozygous PKDH mutations and a high kidney
length-to-width ratio and RNA from 3 mice with
homozygous PKDH mutations and a low kidney length-towidth ratios. The dotted Blue line is the expected distribution of p-values if the treatment has no effect and the solid
Green line is the mixed-model [23] fit of the p-value constrained to be monotonically non-decreasing.

low-up or to investigate more than a few genes. Thus,
while an EDR of 80% or more may be in line with traditional power studies, investigators may not want or have
the laboratory resources to deal with large-scale highpowered gene expression experiments where 1000 s of
genes are identified as differentially expressed. Thus, it
may be more appropriate to have a small list of genes in
which an investigator has high confidence that the genes
identified as differentially expressed are truly differentially
expressed. Thus, modest EDRs (10–40%) may be appropriate when conservative alphas are chosen to generate
high PTPs (80%+). On the other hand, when the investigator wants to get a complete picture of the experimental
manipulations it may be more appropriate to use a liberal
alpha level (0.1) to have a high EDR, but this will yield a
lower PTP. Investigators should carefully consider what
error rate (the proportion of the genes that are studied further that are false positives) is acceptable, how many
genes they can truly invest in studying, and how important it is to have a complete list of differentially expressed
genes.

levels. If the actual experiment were these designs, the calculated sample size may be an over estimate for the methods in the PowerAtlas does not yet allow for using
information from other groups to estimate the variances
as methods such as ANOVA and linear models do. In
addition the hypothesis shown in the main graph may not
be the primary hypothesis of interest in a study, they are
simply the groups with the largest sample sizes, and the
other hypotheses should be reviewed as well. Investigators
should review the primary literature to verify what the true
experimental design was. We also assume the experiments
were conducted in a rigorous fashion and have not been
confounded by non-biological sources of error, which
may adversely effect power nor does the use of good sample size obviate the need for good experimental design
and conduct of the experiment [16].

A few other issues should be considered when choosing
the sample size for an experiment. The first, one should
not rely upon any one study to drive the sample size. An
investigator should view several datasets to get an idea of
the range of possible sample sizes. Secondly, we have analyzed all the data in the PowerAtlas as if it were two groups
with fully randomized designs. This may not be the case;
experiments may be 2 or 3 way experiment with multiple

Future directions
There are several areas where the functions of the PowerAtlas will be expanded. First we will augment the data in the
database by revising the data from GEO every six months
and we will add data from additional sources such as the
Nottingham Arabidopsis Stock Center (NASC). In the PTP
graph at low n and small α, the lines of the PTP sometimes
cross, which is due to the fact under these conditions
sometimes very few or even zero genes are declared significant. As this is the denominator of PTP the PTP is 0. Until
the sample size gets large enough to declare enough genes
differentially expressed at a chosen (small) threshold, PTP
lines may cross over each other. We are working to elimi-
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nate this issue from our method. Currently, only point
estimates of the EDR, PTP and PTN are generated. Future
work will generate confidence intervals on these estimates. We are also extending the power estimation procedures to handle ANOVA and linear models, which will
allow for power estimation for loops designs, the correct
analysis of datasets with multiple groups, and time series
data. When these methods have been developed they will
be incorporated into the PowerAtlas.

Availability and requirements
• Project name: The PowerAtlas
• Project home page: http://www.powerAtlas.org also
http://www.poweratlas.net
• Operating system(s): Web-based application

http://www.biomedcentral.com/1471-2105/7/84

GEO, without which the PowerAtlas would not be possible. This work was
supported by NSF grant 0217651, 0306596 and NIH grant P50AT00477.
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